{
  "id": "nsclc-biomarker-by-method",
  "display_name": "NSCLC Biomarker Testing by Method",
  "cohort": "NSCLC Biomarker Testing, by Method (2024–2025)",
  "insight_type": "Precision Medicine Utilization",
  "summary": "NSCLC testing method adoption varies widely: IHC and FISH >90%, while comprehensive NGS panel testing (52%) lags below target. Increasing NGS utilization represents a $215,000 opportunity.",
  "chart": {
    "type": "bar",
    "unit": "method",
    "data": [
      { "name": "IHC", "value": 95, "gap": 5, "highlight": false },
      { "name": "FISH", "value": 92, "gap": 2, "highlight": false },
      { "name": "PCR", "value": 85, "gap": -5, "highlight": false },
      { "name": "Liquid Biopsy", "value": 63, "gap": -27, "highlight": true },
      { "name": "NGS Panel", "value": 52, "gap": -38, "highlight": true },
      { "name": "RNA-seq", "value": 35, "gap": -55, "highlight": true }
    ],
    "benchmark": 90,
    "nccn_target": 95
  },
  "financial_impact": {
    "annual_opportunity": "$215,000/year",
    "math": "$215,000/year = 38% testing gap (NGS) × 30 NSCLC patients × $18,800 improved therapy matching"
  },
  "clinical_impact": {
    "description": "Comprehensive NGS panel testing significantly improves NSCLC therapy matching and outcomes.",
    "metrics": [
      {
        "type": "PFS",
        "value": "+8.6 months",
        "description": "Improved progression-free survival with NGS-guided therapy"
      },
      {
        "type": "OS",
        "value": "+11.8 months",
        "description": "Overall survival benefit with comprehensive testing"
      },
      {
        "type": "ORR",
        "value": "+47%",
        "description": "Higher objective response rate with matched therapies"
      },
      {
        "type": "CT",
        "value": "+58%",
        "description": "Increased clinical trial eligibility identification"
      },
      {
        "type": "TT",
        "value": "-65%",
        "description": "Reduced need for repeat testing"
      }
    ],
    "quantitative": "+11.8 months OS"
  },
  "peer_comparison": {
    "description": "Leading lung cancer programs utilize NGS panel testing in >85% of cases, vs. your 52%, identifying more actionable alterations.",
    "peer_benchmark": 85,
    "financial_impact": {
      "annual_opportunity": "$295,000/year",
      "math": "$295,000/year = 33% gap to peer benchmark × 45 patients × $19,800 improved care value"
    },
    "action_steps": [
      {
        "text": "Implement NGS-first reflex testing protocol for all advanced NSCLC",
        "icon": "document"
      },
      {
        "text": "Create liquid biopsy pathway for tissue-limited cases",
        "icon": "flask"
      },
      {
        "text": "Develop RNA-seq implementation strategy for fusion detection",
        "icon": "cog"
      },
      {
        "text": "Establish molecular tumor board for complex cases",
        "icon": "users"
      }
    ]
  },
  "weighted_score": 96,
  "action_steps": [
    {
      "text": "Implement universal NGS reflex testing for advanced NSCLC",
      "icon": "document"
    },
    {
      "text": "Create NSCLC-specific tissue collection protocol",
      "icon": "clipboard"
    },
    {
      "text": "Develop liquid biopsy program for insufficient tissue",
      "icon": "flask"
    },
    {
      "text": "Establish testing method tracking dashboard",
      "icon": "chart"
    }
  ],
  "suggestions": [
    {
      "text": "Evaluate tissue acquisition/adequacy challenges",
      "icon": "search"
    },
    {
      "text": "Consider dedicated molecular coordinator role",
      "icon": "user"
    }
  ],
  "drilldowns": [
    {
      "label": "By Provider",
      "cohort": "NSCLC Testing by Provider",
      "jsonFile": "nsclc-biomarker-by-provider.json",
      "drilldownLevel": 3
    },
    {
      "label": "All NSCLC Biomarkers",
      "cohort": "NSCLC Biomarker Testing",
      "jsonFile": "nsclc-biomarker.json",
      "drilldownLevel": 2
    },
    {
      "label": "All Methods",
      "cohort": "Biomarker Testing by Method",
      "jsonFile": "biomarker-compliance-by-method.json",
      "drilldownLevel": 1
    },
    {
      "label": "Overall Compliance",
      "cohort": "Biomarker Testing Compliance",
      "jsonFile": "biomarker-compliance.json",
      "drilldownLevel": 0
    }
  ]
} 